One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Enliven Therapeutics, Inc.
ELVN · NMS · Healthcare · Biotechnology
Current price
$41.96
52-week range
$14.79 - $62.32
Market cap
$3.07B
Balance sheet
Healthy
-7.47x Concerning
Net cash $893.65M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Enliven Therapeutics, Inc.
Enliven Therapeutics develops new medicines for cancer patients, mainly through a drug called ELVN-001 for a type of leukemia and another called ELVN-002 for lung cancer. The money they make comes from the research and development of these potential new treatments, which matters because successfully bringing a drug to market could significantly help patients and generate substantial returns if their medicines prove effective.
How the company got here
Enliven Therapeutics was founded in 2019 with the goal of developing innovative cancer treatments. The company is focused on creating small molecule kinase inhibitors, which are drugs designed to block specific signals that cancer cells use to grow and multiply. Enliven became a public company in 2023 through a merger and has since been advancing its two main drug candidates, ELVN-001 and ELVN-002, through clinical trials. The company's strategy centers on developing targeted therapies for specific types of cancer where current treatments may have limitations.
What it actually does
Enliven Therapeutics is a biopharmaceutical company that develops medicines to treat cancer. They focus on creating 'small molecule kinase inhibitors.' Think of these as highly specific keys designed to fit into the locks (called kinases) that cancer cells use to grow and spread. By blocking these locks, Enliven's drugs aim to stop cancer in its tracks. The company is currently in the 'clinical-stage,' meaning its drugs are being tested in human trials, not yet approved for widespread use.
ELVN-001 (Chronic Myeloid Leukemia)
Enliven's lead drug candidate, ELVN-001, is designed to treat chronic myeloid leukemia (CML). CML is a type of cancer that affects the blood and bone marrow, driven by a specific genetic abnormality called the BCR-ABL gene fusion. ELVN-001 is a 'kinase inhibitor' that specifically targets this abnormality. The drug is currently in Phase 3 clinical trials, which are large-scale studies to confirm its effectiveness and safety before it can be considered for approval by regulatory agencies like the FDA. Enliven is aiming for ELVN-001 to be a best-in-class treatment for CML patients who have previously been treated with other therapies.
ELVN-002 (HER2-mutant Tumors)
The company's other main drug candidate is ELVN-002, which targets cancers with a specific genetic mutation known as HER2. This mutation can be found in various types of cancer, including non-small cell lung cancer (NSCLC) and breast cancer. ELVN-002 is designed to be a potent inhibitor that can also enter the central nervous system (CNS), which is important for treating cancers that may spread to the brain. Enliven has decided to explore strategic alternatives for ELVN-002 to prioritize the development of ELVN-001, meaning they are looking for other options for this program rather than continuing to fund it themselves.
What management is betting on now
Enliven's current strategy is heavily focused on advancing ELVN-001 through its pivotal Phase 3 clinical trials, with the goal of seeking regulatory approval. Management believes ELVN-001 has the potential to be a leading treatment for chronic myeloid leukemia, particularly for patients who have not responded well to existing therapies. By concentrating resources on this program, Enliven aims to demonstrate the drug's efficacy and safety to healthcare providers and regulatory bodies, paving the way for its potential commercialization.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-12.21M
FY2024 Q4
$-17.20M
FY2025 Q1
$-24.15M
FY2025 Q2
$-17.20M
FY2025 Q3
$-13.28M
FY2025 Q4
$-15.84M
FY2026 Q1
$-19.29M
FY2026 Q2
$-18.63M
Revenue
—
Net income
$-32.48M
Diluted EPS
-0.49
Operating cash flow
$-18.53M
Free cash flow
$-18.63M
Fetching…
Sources
Revenue
—
Net income
$-23.63M
Diluted EPS
-0.38
Operating cash flow
$-19.29M
Free cash flow
$-19.29M
Fetching…
Sources
Revenue
—
Net income
$-29.67M
Diluted EPS
-0.45
Operating cash flow
$-15.84M
Free cash flow
$-15.84M
Fetching…
Sources
Revenue
—
Net income
$-20.15M
Diluted EPS
-0.32
Operating cash flow
$-13.28M
Free cash flow
$-13.28M
Fetching…
Sources
Revenue
—
Net income
$-25.34M
Diluted EPS
-0.49
Operating cash flow
$-17.06M
Free cash flow
$-17.20M
Fetching…
Sources
Revenue
—
Net income
$-28.54M
Diluted EPS
-0.57
Operating cash flow
$-24.13M
Free cash flow
$-24.15M
Fetching…
Sources
Revenue
—
Net income
$-23.18M
Diluted EPS
-0.46
Operating cash flow
$-17.20M
Free cash flow
$-17.20M
Fetching…
Sources
Revenue
—
Net income
$-23.16M
Diluted EPS
-0.48
Operating cash flow
$-12.19M
Free cash flow
$-12.21M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $41.96
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $893.6M - more cash than debt. Interest coverage -7.5x.
Net debt
$-893.65M
Interest coverage
-7.47x
Enliven Therapeutics, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
ELVN
BASELINE
Enliven Therapeutics, Inc.
Total debt $1.51M Interest coverage -7.47x This is the baseline the peer rows are being compared against.
What you should know
The case for and against ELVN
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -15.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-18.11x
P/B
3.43x
P/S
—
EV/EBITDA
-17.13x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-15.3%
ROA
-11.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
64.07x
Quick ratio
63.21x
Total debt
$1.51M
Total cash
$895.16M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.67
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-66.94M
Free CF TTM
$-70.46M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—